Plain-English translation of NCT05003986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help children with certain types of kidney disease that cause protein to leak into the urine. The study will follow about 67 children for nearly 2 years to measure how well the medication works and how safe it is. Researchers are particularly interested in children with focal segmental glomerulosclerosis, minimal change disease, IgA nephropathy, IgA vasculitis, or Alport syndrome.
Children with these kidney diseases often lose too much protein in their urine, which can lead to kidney damage over time. This medication targets a different pathway in the body than current treatments, and researchers want to learn whether it could help protect children's kidneys and reduce protein loss.
You likely qualify if…
You likely don't qualify if…
You would take the study medication by mouth and visit the clinic multiple times over about 2 years. At each visit, you'll have blood and urine tests to check how your kidneys are working and how much protein you're losing. The study team will also monitor your blood pressure and check for any side effects. Depending on which group you're in, you may have more frequent visits and blood draws early on, then less frequent ones as the study continues.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
United States